Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BE-MOBILYZED belimumab study in highly sensitized kidney transplant candidates
2023-508116-32-00Phase 2Authorised
- Sponsor
- Leiden University Medical Center
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belimumab in HLA sensitization, sponsored by Leiden University Medical Center. Primary endpoint: Change in number of HLA specificities detected from stimulated memory B-cell supernatants after 4 weeks. Planned start Nov 2025; status: authorised.
02
Drugs
belimumab
03
Conditions
HLA sensitization
Beyond the preview
Go deeper on 2023-508116-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508116-32-00.